Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 313

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 313
---
platform which measures an individual’s biochemistry that is easy to use, cost -effective, and provides the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users while collecting actionable data potentially for clinical trial and pharmaceutical development. Additional product applications include lactate, sodium, CO 2and ethanol monitoring. (v) Ready to go public with a substantial infrastructure and with minimal cash needs to meet milestones:Profusa is based in the U.S. with global prospects and investor interest. Profusa plans to manage operations the U.S. while manufacturing with contractors or partners regionally. (vi) Strong Investor Support:Profusa has raised over $70 million in capital to date in the private markets and over $30 million in non -dilutivefunding by DARPA and NIH demonstrating broad based interest. Strategic, global investors and potential partners have also demonstrated interest in providing financial support. • Profusa’s post -closing condition.The NorthView Board also considered factors such as Profusa’s outlook, financial plan and debt structure, taking into consideration the fact that, after consummation of the Merger, Profusa will have approximately $15 million of cash on its balance sheet (which condition was subsequently waived on the condition that the combined company is able to meet Nasdaq’s minimum listing requirements), positioning it to execute its plan to: (i)Ramp up operations to produce sensors, readers and launch its AI platform. (ii)Complete pivotal studies and obtain approval of the Lumee Oxygen product in the US. File for FDA approval of the Lumee CGM product. (iii)Build commercial resources and operational capabilities. (iv)Commercialize the Lumee Oxygen product and prepare for and execute commercial launch of the Lumee CGM product. • Purchase price paid by the Company to Profusa is fair to the Company from a financial point of view.Based on Marshall & Stevens’ fairness opinion, NorthView Management’s analysis and legal due diligence, the NorthView Board determined that the value of the consideration to be deliver by the Company to Profusa shareholders is fair to the Company from a financial point of view. Marshall & Stevens specifically provided the opinion that the value of the consideration to be provided by the Company to Profusa shareholders in the Merger, as provided in the Merger Agreement, is fair to the Company from a financial point of view. 161 The NorthView Board also considered a variety of uncertainties, risks and other potentially negative factors relating to the Merger including, but not